Doctors in Washington State gave remdesivir (Gilead antiviral drug) to the first coronavirus patient in the United States last week after his condition worsened and pneumonia developed when he’d been in the hospital for a week. His symptoms improved the next day.
Two clinical trials will take place in Wuhan, China, the center of the outbreak; 500 patients will receive the drug, and comparison groups will get a placebo. The patients will get the drug intravenously for 10 days, and then assessed 28 days after the treatment to see how they fared compared to the placebo groups
Remdesivir and chloroquine (anti-malarial) stops coronavirus in the lab.
There are currently limited available clinical supplies of remdesivir, but Gilead is working to increase the available supply as rapidly as possible. They had stockpiled the drug in case of an Ebola outbreak.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.